NEW YORK, NY. USA I January 10, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating ...

BELTSVILLE, MD, USA I January 10, 2025 I NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing ...

INCHEON, Korea and TEL AVIV, Israel I January 10, 2025 I Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced ...

TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC--First patient expected to be dosed in SURF302 in Q2 2025-CARLSBAD, CA, USA I J ...

Ouro will leverage $120 million in funding to develop novel T cell engagers with potential to reset the immune system in patients with chronic immune-mediated ...

Clinical-stage CAR T company dosed first patient for Phase 1 trial to evaluate SynKIR™-310, a new drug candidate for relapsed/refractory B cell Non-Hodgkin ...

The primary objective of this initial clinical trial is to evaluate safety and immune responses of three different dose levels and two different vaccination schedules of ARCT-2304 vaccine. Immune ...

UTRECHT, The Netherlands and PHILADELPHIA, PA, USA I January 10, 2025 I LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage ...

Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients ...

CRANFORD, NJ, USA I January 7, 2025 I Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, ...

Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 ...

New investor Jeito Capital, a global leading private equity fund, led the Series B financing round which also included existing institutional investors EQT, Fountain Healthcare Partners, and Lumira ...